Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange
About Dr.
Dr.
Previously, she served as President and Chief Medical Officer at Kriya Therapeutics, where she launched the ophthalmology division, Kriya Ophthalmology, and was responsible for building its AAV gene therapy portfolio strategy. Prior to joining Kriya, Theresa served as Executive Vice President of Operations and Chief Medical Officer at AsclepiX Therapeutics, where she led the company’s advancement of its pipeline products into the clinic. She also previously served as Chief Medical Officer at Applied Genetic Technologies Corporation, working to develop gene therapies in ophthalmology and rare diseases. In addition, she has held several leadership positions with increasing responsibility in early-stage private companies (
“We welcome
“I share the enthusiasm and look forward to collaborating with the esteemed leadership and scientists at Curative Biotechnologies in developing and advancing innovative products aimed at preserving vision” expressed
Future Curative Biotechnology Press Releases and Updates
Interested investors and shareholders can be notified of future press releases and industry updates by e-mailing ir@curativebiotech.com
About
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact:
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com
Source:
2024 GlobeNewswire, Inc., source